nk1999
02 Feb 2018
Numis "Numis: Horizon trading at discount despite strong growthGene-editing company Horizon Discovery (HZD) is trading at a ‘significant’ discount to peers despite matching their growth, says Numis. Analyst Paul Cuddon retained his ‘buy’ recommendation and target price of 300p on the shares, which fell 8.2% to 212p yesterday. The company expects to report 51% sales growth for full-year 2017 to £36.4 million, driven by higher margin diagnostic and biomanufacturing products and the acquisition of Dharmacon. ‘Having delivered savings throughout the year, Horizon achieved profitability in the fourth quarter and with the integration of Dharmacon ongoing is well placed heading into 2018 where the outlook for growth remains strong,’ he said. ‘The shares trade on 5x enterprise value/2018 sales, which is a significant discount to the wider tools peer group at 7x, delivering similar underlying growth and gross margins.’"(From Citywire)
Bluemogganer
01 Feb 2018
Re: Great Update ....strange the SP drops 9% though!
pied kingfisher
01 Feb 2018
Great Update [link]
d gaser
19 Jul 2017
Horizon to acquire Dharmacon Horizon to acquire DharmaconStockMarketWire | Wed, 19th July 2017 - 07:38 Horizon Discovery Group has agreed to acquire Dharmacon from General Electric Company for a total consideration of $85 million (£65 million), subject to a working capital adjustment at completion.Horizon said that upon completion, which was conditional on the approval of the placing by Horizon shareholders and anti-trust clearance in the US, General Electric Company would receive $50 million in cash and a subsidiary of General Electric Company would be issued with $35 million in new ordinary shares in Horizon to be valued at the placing price of 205 pence, equating to 13,064,868 new ordinary shares (representing 8.8% of the enlarged share capital of Horizon).The company also announces that it would raise £76.4 million, net of expenses, through the issue of 39,024,390 new ordinary shares at 205p apiece.BE HAPPYDave [link]
paul1945
06 Dec 2016
Director buying 4 dir + 100,000. Dr Johnathan Milner non ex +90,000. Founder of Abacam & Pharma superstar. Woodford also a holder
nk1999
20 Oct 2016
Numis From Citywire:"‘Biologic’ era benefits Horizon Discovery, says Numis Gene-editing company Horizon Discovery (HZDH) has improved efficiency and is driving its product line, believes Numis Securities.Analyst Paul Cuddon retained his ‘buy’ recommendation and target price of 260p on the stock, commenting: ‘Biologic drugs have taken over from small chemical modules as the best-selling drugs worldwide, and now underpin the pipelines of the vast majority of pharmaceutical and biotech companies.’‘These drugs are primarily manufactured in Chinese hamster ovary cells and Horizon has used its gene-editing expertise to modify this gold standard cell line to improve the efficiency of production and provide more flexible licensing terms for drug developers,’ he added.‘This agreement further highlights an additional driver of the products business that underpins our growth expectations in the years ahead, and further reflects Horizon’s ability to leverage its gene-editing technology into markets beyond research and companion diagnostics,’ Cuddon said.The shares were unchanged at 137.4p."
Sambram
13 Sep 2016
CPI partnership "An announcement this morning sees Horizon expand the application of its bioproduction cell line platform with new partnerships with the Centre for Process Innovation (CPI, UK) and the National Institute for Bioprocessing Research and Training (NIBRT, Ireland). This continues the strategic-style news flow from Horizon where partnering and collaboration agreements are established, not for the headline numbers, but for their potential to build revenue streams over the long term."Update from Panmure, out this morning on Research Tree
Simbr
02 Jun 2016
QIAGEN Following Horizon's announcement on 12th of May of a deal with an NGS Company, we are now given the name of the Company - QIAGEN N.V. a US$5bn NASDAQ and Frankfurt listed global leading NGS platform enterprise. Importantly, the deal demonstrates the impact Horizon's Reference Standards are having in supporting the rapidly growing NGS market. Further, future joint collaborations are expected as work continues to unlock the full clinical and research potential of both technologies. In addition, QIAGEN's GeneRead QIAact Actionable Insights Tumor Panel is the first in a family of multiplex panels for the GeneReader NGS System targeting the most prevalent types of cancer research, including breast, ovarian, colorectal, lung and melanoma. The accuracy, consistency and reliability of this Panel was validated through extensive testing compared with the control data derived from Horizon's Reference Standards, proving its performance. Yesterday's announcement validates further the quality of the Horizon Discovery's services on offer. We believe there is more opportunities for Horizon Discovery in this space. beaufort's note on researchtree
Simbrad
02 Jun 2016
Beaufort's note published this morning on Research Tree... "Following Horizon's announcement on 12th of May of a deal with an NGS Company, we are now given the name of the Company - QIAGEN N.V. a US$5bn NASDAQ and Frankfurt listed global leading NGS platform enterprise. Importantly, the deal demonstrates the impact Horizon's Reference Standards are having in supporting the rapidly growing NGS market. Further, future joint collaborations are expected as work continues to unlock the full clinical and research potential of both technologies. In addition, QIAGEN's GeneRead QIAact Actionable Insights Tumor Panel is the first in a family of multiplex panels for the GeneReader NGS System targeting the most prevalent types of cancer research, including breast, ovarian, colorectal, lung and melanoma. The accuracy, consistency and reliability of this Panel was validated through extensive testing compared with the control data derived from Horizon's Reference Standards, proving its performance. Yesterday's announcement validates further the quality of the Horizon Discovery's services on offer. We believe there is more opportunities for Horizon Discovery in this space. We..."
nk1999
18 Jan 2016
Good results "Cambridge, UK - 18th January 2016: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or the "Group"
, the international life science tools business today announces a trading update ahead of its full year results for the twelve months ended 31 December 2015. The Group intends to announce its preliminary full year 2015 results on 26 April 2016.The Group reports a second consecutive year of on-target performance since its IPO, with full year 2015 revenues expected to be at least 2% ahead of the £19.8 million market consensus, representing growth of at least 69% (year ended 31 December 2014: £11.9 million). In addition, the Group is eligible to receive future R&D milestones of up to £208 million plus future product royalties, an increase of 32% over the prior year (year ended 31 December 2014: £158m). Revenue growth is reflective of strong product and service sales to large pharmaceutical and diagnostic development companies as well as an increasing number of academic customers purchasing from a product inventory that increased from 2,750 to 23,000 in the year.....................Year-end cash is expected to be reported at £25.1 million (year ended 31 December 2014: £18.5 million)." Looks good to me.nk
Ripley94
15 Nov 2015
DIRECTOR BUYS. ALWAYS GOOD
KestleMill
02 Oct 2015
Crispr Bad news for Horizon and others who have paid for licenses for the CRISPR/Cas9 gene editing technology! [link] seems there are other proteins other than Cas9 that can do the same job only better. Implications: i) There are going to be many gene editing proteins out there, so companies such as Horizon won't have to pay so much for licences, ii) the winner of the race to cash in on gene editing services will not just be limited to those with the most money who can afford the licenses, it will be about who is best at marketing and who can enable their customers to get their gene editing done in the most efficient way. The new technology should fit with Horizon's current approach of offering a portfolio of gene editing technologies. Having Fang Zheng (who found the new gene editing protein) on the advisory board must also help. On the marketing side, they are up against some big players like Origene and ThermoFisher. They will have less to invest in pushing Cripsr but also should be able to have more laser-like focus on it than their larger rivals.
pharmaspecialist
09 Sep 2015
Re: Placing and share price Hello Kestlemill,Yes I agree it is very hard to value this company and you can, indeed, expect more dilution. I like the agreement with Abcam just announced but I prefer Abcam as an investment because its business is less speculative, easier to value and it throws out cash rather than consuming it. I would advise taking no notice of what Mr. Woodford invests in. His training was in economics and he has worked in insurance and as a fund manager with great success in selecting equity income investments. I am sure he must have done a crash course in biotech but, speaking as an investor with 25 years experience of the UK and US biotech industry, I find it hard to work out how he has developed the expertise to invest in this sector which, believe me, is fundamentally different from equity income investing. I assume he must be outsourcing the due diligence on his biotech investments and I have a feeling that he is adpopting a "scatter gun" approach as I can see no rhyme or reason with the companies he is choosing, some of which are look excellent to me and some appear to be no-hopers.
KestleMill
28 Jul 2015
Re: Placing and share price Claude, Thank you for your thought provoking post. Here are two thoughts it has provoked:i) This is currently a cash-hungry, acquisitive and loss-making (but fast-growth) business which is likely going to wish to raise more money in order to aggressively pursue its strategy. So we can expect further dilution.ii) On the other hand, if Woodford thinks it is worth a punt at 190 shouldn't we also?For me the key to the business is whether they can become the go-to company for the CRISPR technology. Other good businesses like Origene have CRISPR licenses but HZD have the links into pharma - probably they are after different segments. I think HZD will succeed and I am very tempted to get in at this level. However, I do find it very hard to value this business. KestleMill
nk1999
20 Jul 2015
Trading update Summary from a news bulletin:"Horizon Discovery Group Plc (HZD.L) Announced, in its trading update for the six months ended 30 June 2015, that the revenues stood at £8.6 million, 112% growth from the previous year (six months to 30 June 2014: £4.1 million). The group receivables for future R&D stood at £158 million plus future product royalties (six months to 30 June 2014: £120 million). In the product segment, revenue was approximately £3.0 million during the period, representing strong period on period growth and continues to represent an increasing proportion of total group revenues. Significant expansion in the cell line and diagnostic reagent product inventory to around 16,500 products (six months to 30 June 2014: around 2,750) driven by internal product development and the integration of the cell line inventory acquired through the acquisition of Haplogen Genomics GmbH in the period. The company expanded sales channel for cell line products in the rapidly growing genomics research market via an agreement signed with Thermo Fisher Scientific that provides global reach and supply into academic laboratories. The company expanded sales channel for diagnostic reagent products through Original Equipment Manufacturing (OEM) partnerships with ArcherDX, CareDx and Transgenomic. It launched its first commercially available engineered mammalian cell line for use in manufacturing of therapeutic antibodies. The product has generated significant early revenues and is anticipated to be a further driver of growth going forward. Services business performance was in line with expectations, delivering revenue of approximately £5.4 million, representing significant growth on the previous year, based in part on the successful integration of acquisitions within its core business. It launched new genetic screening services, including on the company’s CRISPR-Cas9 sgRNA technology platform, that has generated several contracts and is expected to be a significant driver of future growth."
